Clinical Trials Directory

Trials / Completed

CompletedNCT02880007

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Institut de Cancérologie de Lorraine · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer.

Detailed description

* The causes of treatment failure and death in cervical cancer are still often linked to a local cancer progression * The importance of local control for healing, than the cervix situation in the center of pelvis between bladder and rectum which are sensitive organs to irradiation justify the use of utero-vaginal brachytherapy * This open label, multicenter, phase II study evaluates the benefit of increasing in dose to the target volume at high risk and the intermediate target volume in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer. * Local control and tolerance are evaluated

Conditions

Interventions

TypeNameDescription
RADIATIONExternal Beam Radiation Therapy45 Gy pelvis / 25 fr
RADIATIONPDR Brachytherapy1 puls/hour ; 12 Gy / day
DRUGCisplatinincrease in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy

Timeline

Start date
2011-06-06
Primary completion
2014-02-10
Completion
2019-07-01
First posted
2016-08-26
Last updated
2020-03-10

Locations

9 sites across 1 country: France

Source: ClinicalTrials.gov record NCT02880007. Inclusion in this directory is not an endorsement.